Lipocine Stock Today

LPCN -  USA Stock  

USD 1.01  0.04  3.81%

Market Performance
0 of 100
Odds Of Distress
Less than 10
Lipocine is selling for 1.01 as of the 5th of December 2021. This is a -3.81 percent decrease since the beginning of the trading day. The stock's open price was 1.05. Lipocine has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Lipocine are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 6th of September 2021 and ending today, the 5th of December 2021. Click here to learn more.
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. The companys pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase II Clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis TLANDO XR, an oral prodrug of testosterone for once daily dosing, which has completed Phase II clinical trial in hypogonadal men LPCN 1148, an oral prodrug of bioidentical testosterone that has completed phase I clinical trial for the treatment of NASH cirrhosis and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company has 88.29 M outstanding shares of which 3.7 M shares are now shorted by private and institutional investors with about 3.97 trading days to cover. More on Lipocine

Lipocine Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Lipocine's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Lipocine or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Lipocine generated a negative expected return over the last 90 days
Lipocine has some characteristics of a very speculative penny stock
Lipocine has high historical volatility and very poor performance
Net Loss for the year was (19 M) with loss before overhead, payroll, taxes, and interest of (5.05 M).
Lipocine currently holds about 46.64 M in cash with (14.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.53.
Lipocine has a frail financial position based on the latest SEC disclosures
Latest headline from MacroaxisInsider: Purchase by Mahesh Patel of 25000 shares of Lipocine
Lipocine Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Lipocine SEC Filings
Lipocine SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameLipocine
ChairmanMahesh Patel  (View All)
Average Analyst Recommendation
Analysts covering Lipocine report their recommendations after researching Lipocine's financial statements, talking to executives and customers, or listening in on Lipocine's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Lipocine. The Lipocine consensus assessment is calculated by taking the average forecast from all of the analysts covering Lipocine.
Strong Buy3 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Lipocine based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Lipocine financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 3 - FrailDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares60.1 M55.7 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares Diluted60.1 M55.7 M
Significantly Up
Increasing
Slightly volatile
Total Assets27.4 M25.4 M
Significantly Up
Increasing
Slightly volatile
Total Liabilities8.1 M10 M
Significantly Down
Increasing
Slightly volatile
Current Assets27.4 M25.3 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities5.2 M6.6 M
Significantly Down
Increasing
Slightly volatile
Total Debt6.2 M5.6 M
Significantly Up
Decreasing
Slightly volatile
Return on Average Assets(0.91)(0.887)
Fairly Down
Decreasing
Slightly volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile
Asset Turnover0.00740.0072
Fairly Up
Decreasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Lipocine's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong HoldUndervalued
Financial Strength
Lipocine's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Lipocine's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Lipocine's financial leverage. It provides some insight into what part of Lipocine's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Lipocine's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Lipocine deploys its capital and how much of that capital is borrowed.
Liquidity
Lipocine cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 4.18 M in liabilities with Debt to Equity (D/E) ratio of 0.12, which may suggest the company is not taking enough advantage from borrowing. Lipocine has a current ratio of 5.24, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Operating Cash Flow

(16.51 Million)Share
Lipocine (LPCN) is traded on NASDAQ Exchange in USA. It is located in 675 Arapeen Drive and employs 13 people. Lipocine is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with current market capitalization of 90.06 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Lipocine's market, we take the total number of its shares issued and multiply it by Lipocine's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Lipocine conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 88.29 M outstanding shares of which 3.7 M shares are now shorted by private and institutional investors with about 3.97 trading days to cover. Lipocine currently holds about 46.64 M in cash with (14.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.53.
Check Lipocine Probability Of Bankruptcy
Ownership
Lipocine maintains a total of eighty-eight million two hundred ninety thousand outstanding shares. Roughly 87.0 % of Lipocine outstanding shares are held by regular investors with 2.51 pct. owned by insiders and only 10.64 % by institutional investors. Please note that no matter how much assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Lipocine Ownership Details

Lipocine Stock Price Odds Analysis

What are Lipocine's target price odds to finish over the current price? Proceeding from a normal probability distribution, the odds of Lipocine jumping above the current price in 90 days from now is more than 94.0%. The Lipocine probability density function shows the probability of Lipocine stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Lipocine has a beta of 0.847. This indicates as returns on the market go up, Lipocine average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Lipocine will be expected to be much smaller as well. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Lipocine is significantly underperforming DOW.
 Odds Down 1.01HorizonTargetOdds Up 1.01 
5.95%90 days
 1.01 
93.99%
Based on a normal probability distribution, the odds of Lipocine to move above the current price in 90 days from now is more than 94.0 (This Lipocine probability density function shows the probability of Lipocine Stock to fall within a particular range of prices over 90 days) .

Lipocine Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Lipocine that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Lipocine's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Lipocine's value.
InstituionSecurity TypeTotal SharesValue
Vanguard Group IncCommon Shares3.8 M4.2 M
Blackrock IncCommon Shares1.6 M1.7 M
Group One Trading LpCall Options625.5 K682 K
Simplex Trading LlcPut Options75.8 K106 K
View Lipocine Diagnostics

Lipocine Historical Income Statement

Lipocine Income Statement is one of the three primary financial statements used for reporting Lipocine's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Lipocine revenue and expense. Lipocine Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Lipocine Income Tax Expense is quite stable at the moment as compared to the past year. The company's current value of Income Tax Expense is estimated at 248.16 View More Fundamentals

Lipocine Stock Against Markets

Picking the right benchmark for Lipocine stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Lipocine stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Lipocine is critical whether you are bullish or bearish towards Lipocine at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Lipocine without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Pattern Recognition Now

   

Pattern Recognition

Use different Pattern Recognition models to time the market across multiple global exchanges
All  Next Launch Module

Lipocine Corporate Directors

Lipocine corporate directors refer to members of a Lipocine board of directors. The board of directors generally takes responsibility for the Lipocine's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Lipocine's board members must vote for the resolution. The Lipocine board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Richard Ono - DirectorProfile
Jeffrey Fink - DirectorProfile
Stephen Hill - Lead Independent DirectorProfile
John Higuchi - Non-Executive DirectorProfile
Additionally, see Stocks Correlation. Note that the Lipocine information on this page should be used as a complementary analysis to other Lipocine's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Lipocine Stock analysis

When running Lipocine price analysis, check to measure Lipocine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lipocine is operating at the current time. Most of Lipocine's value examination focuses on studying past and present price action to predict the probability of Lipocine's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Lipocine's price. Additionally, you may evaluate how the addition of Lipocine to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Is Lipocine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine Lipocine value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.